Business UpdateJul 1, 2026, 04:14 PM
Biogen expects Q2 R&D expense $164M, Q3 $290M-$320M
AI Summary
Biogen Inc. expects to incur significant acquired in-process research and development, upfront, and milestone expenses for the second and third quarters of 2026. For Q2 2026, a pre-tax charge of approximately $164 million is anticipated, impacting diluted EPS by about $0.95. For Q3 2026, expenses are projected to range from $290 million to $320 million, with an estimated diluted EPS impact of $1.75 to $1.95. These figures are preliminary and subject to change as the company does not typically forecast such uncertain expenses.
Key Highlights
- Expected Q2 2026 acquired R&D, upfront, and milestone expense: approximately $164 million pre-tax.
- Estimated Q2 2026 impact on GAAP/non-GAAP diluted EPS: approximately $0.95 per share.
- Anticipated Q3 2026 acquired R&D, upfront, and milestone expense: $290 million to $320 million.
- Estimated Q3 2026 impact on GAAP/non-GAAP diluted EPS: $1.75 to $1.95 per share.
- Q3 expenses relate to potential milestones and transactions not yet closed.
- Biogen does not forecast such expenses due to uncertainty of future occurrence and timing.
- Q2 2026 results are preliminary and subject to financial statement closing procedures.
Price Impact
More from BIIB